Talphera Reports Q4/FY25 Results, Boosts Cash to $20.4M, Achieves 50% Enrollment in Key CRRT Study

summarizeSummary

Talphera, Inc. announced its fourth quarter and full year 2025 financial results, reporting increased losses but a significantly strengthened cash position of $20.4 million and reaching 50% enrollment in its pivotal NEPHRO CRRT clinical study.

check_boxKey Events

• Q4/FY25 Financial Results

  Reported a Q4 2025 net loss of $3.8 million, widening from $1.9 million in Q4 2024, with full-year 2025 net loss at $14.29 million. Basic and diluted loss per share for Q4 2025 was $0.06, an improvement from $0.07 in Q4 2024.

• Strengthened Cash Position

  Cash and investments increased significantly to $20.4 million as of December 31, 2025, up from $8.86 million at the end of 2024, providing substantial liquidity for future operations.

• Clinical Study Milestone Achieved

  Reached 50% (35-patient) enrollment in the pivotal NEPHRO CRRT registrational study for Niyad in March 2026, with all 12 clinical sites now actively enrolling patients to support an expected study completion in 2026.

• 2026 Operating Expense Guidance

  Projected cash operating expenses for 2026 to be in the range of $17 million to $18 million, an increase from approximately $13 million in 2025, primarily due to expenses related to finalizing the NEPHRO CRRT trial.

auto_awesomeAnalysis

This filing provides a critical update on Talphera's financial health and operational progress. Despite widening net losses for Q4 and full year 2025, the company significantly improved its cash and investments balance to $20.4 million, providing crucial runway for its operations. This cash position, representing over 50% of its market capitalization, is a strong positive for a company that recently received a Nasdaq non-compliance notice. Furthermore, achieving 50% enrollment in the NEPHRO CRRT registrational study is a significant clinical milestone, indicating progress towards potential FDA approval for its lead product candidate, Niyad. Investors should monitor the company's continued enrollment progress and its ability to manage increased operating expenses in 2026 as it finalizes the trial.